Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gypensapogenin I
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Gypensapogenin I is a biologically active saponin compound extracted from the traditional Chinese herbal medicine *Gynostemma pentaphyllum*. It has demonstrated therapeutic potential in the treatment of ulcerative colitis by reducing intestinal inflammation and modulating the gut microbiota. Mechanistically, gypensapogenin I targets AKT serine/threonine kinase 1 (AKT1), thereby modulating the PI3K/AKT signaling pathway. Research indicates its efficacy in both in vivo and in vitro models of intestinal disease, where it helps restore microbial balance and suppress inflammatory responses.
- Other names
- GI
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CTNNB1 (Beta-catenin)GSK3 (Glycogen synthase kinase 3 beta)NOTCH (Neurogenic locus notch homolog protein 3)
Beyond the preview
Go deeper on gypensapogenin I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gypensapogenin I.